Acutaas Chemicals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹306Cr
- +23.9% YoY
- +47.8% QoQ
- Net profit
- ₹72Cr
- +89.5% YoY
- +63.6% QoQ
- Margin
- 31%
- +11 pp YoY
- +6 pp QoQ
Guidance rank: #17 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). - Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). - New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). - Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15). - Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6). - Capital expenditures focused on growth (INR 210 crores approx.
From Acutaas Chemicals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26.
- Higher growth is expected from the CDMO business segment compared to traditional Pharma Intermediates.
- Electrolyte additives segment is expected to start contributing from Q4 FY '26 and more significantly in FY '27, with full visibility on capex and products.
- Semiconductor JV in South Korea is projected to start commercial production in H2 FY '27, contributing to revenue thereafter.
- Specialty Chemicals segment is expected to grow around 10-15% in FY '26.
2 more points from Acutaas Chemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth.
- Major growth capex includes INR 180 crores for electrolyte additive plant at Jaghadia and INR 30 crores for pilot plant at Sachin.
- Electrolyte additive capex expected to complete by Q4 FY '26 and start contributing from Q4 FY '26, fully ramping by FY '27.
- South Korea JV (Indichem) capex underway, commercial production expected in H2 FY '27; Acutaas holds 75% stake.
- Beyond FY '26, all planned growth capex expected to be completed; future capex to be mainly maintenance.
2 more points from Acutaas Chemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Validation batches for new CDMO contracts have been sent during the quarter.
- Commercial production for these new CDMO products is expected to start by the last quarter of FY '26, subject to regulatory approvals.
- Full visibility exists for the CDMO business for the current year and projections for the next years, indicating a healthy order book.
- The Block 3 at Ankleshwar, commissioned last year, is operational and catering to projected customer requirements.
- For electrolyte additives, the planned capacity (2,000 metric tons each for VC and FEC) is based on signed contracts, providing full visibility on demand.
2 more points from Acutaas Chemicals Ltd's call on order book
Create a free account to keep reading this call
Acutaas Chemicals Ltd — Quarterly revenue & net profit
Acutaas Chemicals Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 306 | 247 | +23.9% | 207 | +47.8% |
| Operating profit (EBITDA) | 95 | 49 | +93.9% | 51 | +86.3% |
| Operating margin | 31% | 20% | +11 pp | 25% | +6 pp |
| Profit before tax | 96 | 50 | +92% | 58 | +65.5% |
| Net profit (PAT) | 72 | 38 | +89.5% | 44 | +63.6% |
| EPS (₹) | 8.82 | 4.56 | +93.4% | 5.41 | +63% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹437 Cr, net profit ₹123 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Acutaas Chemical's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Acutaas Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q2 FY26 results?
The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). - Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). - New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). - Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15). - Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6). - Capital expenditures focused on growth (INR 210 crores approx.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 69.6 with a market cap of ₹26,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth.
Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
